## 012604

## **UTILITY PATENT APPLICATION TRANSMITTAL**

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Date of Deposit

Signatury Fames W. Bolcsal

EL964822216 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: FRAV2003/0001 US NP

INVENTORS: Alain Le-Brun, et al TITLE: PRODUITS N-ARYL-

HETEROAROMATIQUES,

**COMPOSITIONS LES CONTENANT ET** 

**UTILISATION** 

## **APPLICATION ELEMENTS**

1.	$\boxtimes$	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)					
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	olications ored R & D				
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets				
4.	Oath a.	or Declaration  Newly unexecuted (original or copy)	Total Pages	2			
	b.	Copy from a prior application (37 CFR § 1	.63(d))				
		i. DELETION OF INVENTOR(S) Signed statement attached deleting application, see 37 CFR §§ 1.63(d)(2)		ned in the prior			
5.	Powe	er of Attorney  Newly executed (original or copy)	Total Pages				
	b.	Copy from a prior application (37 CFR § 1	.63(d))				
6.		Microfiche Computer Program (Appendix)					

rage	62						
7.	Nucleotide and/or Amino Acid Sequence S (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to compute. Statement verifying identity of a	uter copy)					
$\boxtimes$	This application claims the benefit of U.S. Provisional Application No. 60/455,120, filed March 17, 2003 and claims priority of French Application No. 0300894 filed January 28, 2003. (The cross reference has been/will be inserted on page one of the specification).						
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
ACC	COMPANYING APPLICATION PARTS						
7.	Assignment Papers (cover sheet & docu	ument(s))					
8.	37 CFR §3.73(b) Statement (when there is an assignee)	· //					
9.	Verified English Translation Docume	ent (if applicable)					
10.		Copies of IDS Citations					
11.	<u> </u>						
12.		3)					
13.	*Small Entity Statement(s) (PTO/SB/09-12)	Statement filed in prior application, Status still proper and desired					
14.	Certified Copy of Priority Document(s	· ·					
15.	Other: Application Data Sheet (4 p	ogs.)					
COF	CORRESPONDENCE ADDRESS						
$\boxtimes$	Customer Number or Bar Code Label	005487					
	(Ins	nsert Customer No. or Attach bar code label here)					
	<del></del>	I am W. Bland					
		nes W. Bolcsak, Reg. No. 39,912 omey/Agent for Applicant					

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-5922
Telefax (908) 231-2626
Aventis Docket No. FRAV2003/0001 US NP

Application Transmittal Letter

Approved for use through 04/30/2003. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

FRAV2003/0001 US NP

Complete if Known

Not Yet Assigned

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

770.00

FEE	TR/	AN:	SMI'	TT	AL
	for I	FY	200	4	

TOTAL AMOUNT OF PAYMENT

Concurrently Filed H rewith Filing Date Alain Le-Brun, et al First Named Inventor Patent fees are subject to annual revision. **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 Group / Art Unit

Attorney Docket No.

**Application Number** 

METHO	DD OF F	PAYMI	ENT (check all that a	pply)		FEE CALCULATION (continued)				
Check	Credit Ca	rd _	Money Other	None	3. A	DITIO	NAL F	EES		
Deposit Account					Large Er		Small E			
Deposit Account Number			18-1982		Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Deposit		4.	T)						ree Description	ree Paid
Account Aventis Pharmaceuticals Inc.					1051	130	2051	65	Surcharge - late filing fee or oath	
_			zed to: (check all that		1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
Charge fee(s) indicated below Credit any overpayments Charge any additional fee(s) during the pendency of this application					1053	130	1053	130	Non-English Specification	
			• • •		1812 1804	2,520 920*	1812 1804	2,520 920*	For filing a request for reexamination Requesting publication of SIR prior to	
to the abov			except for the filing fee account		1004	920	1804	320	Examiner action	
	FEE	CALC	CULATION		1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FI					1251	110	2251	55	Extension for reply within first month	
Large Entity Fee Fee	Small E	Fee	Fee Description	Fee Paid	1252	420	2252	205	Extension for reply within second month	
Code (\$) 1001 770	Code 2001	( <b>\$)</b> 375	Utility filing fee	770	1253	950	2253	465	Extension for reply within third month	
1002 340	2002	165	Design filing Fee		1254	1,480	2254	725	Extension for reply within fourth month	
1003 530	2003	260	Plant filing fee		1255	2,010	2255	985	Extension for reply within fifth month	
1004 770	2004	375	Reissue filing fee		1401	330	2401	160	Notice of Appeal	
1005 160	2005	80	Provisional filing fee		1402	330	2402	160	Filing a brief in support of an appeal	
SUBTOTAL (1) (\$) 770.00					1403	290	2403	140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE					1451	1,510	1451	1,510	Petition to institute a public use proceeding	
Fee Extra from Fee					1452	110	2452	55	Petition to revive - unavoidable	
Claims below Paid  Total Claims × = = =				1453	1,330	2453	650	Petition to revive - unintentional		
Independent 5	:	3**=	-	_ [	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims					1502	480	2502	235	Design issue fee	
Multiple Depende	ent			=	1503	640	2503	315	Plant issue fee	
					1460	130	1460	130	Petitions to the Commissioner	
Large Entity Fee Fee	Small E Fee	ntity Fee			1807	50	1807	50	Petitions related to provisional applications	
Fee Fee Code (\$)	Code	(\$)	Fee Description						applications	
1202 18	2202	9	Claims in excess of 20		1806	180	1806	180	Submission of Information Disclosure Stmt	
1201 86	2201	42	Independent claims in e	excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1203 290	2203	140	Multiple dependent clai paid	m, if not	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86	2204	42	**Reissue independent claims over original p		1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18	2205	9	**Reissue claims in exc 20 and over original p		1801	770	2801	375	Request for Continued Examination (RCE)	
					1802	900	1802	900	Request for expedited examination of a design application	
	SUB	TOTAL	L (2) (\$)		Other fee	(specify)				
**or number previously paid, if greater; For Reissues, see above			*Reduce	d by Basic	Filing Fee	e Paid	SUBTOTAL (3) (\$)	-		

SUBMITTED BY Complete (If applicable) Registration No. Name (Print/Type) James W. Bolcsak, Reg. No. 39,912 39,912 Telephone (908) 231-5922 (Attomey/Agent) 2004 Signature Date

> WARNING: Information on this f rm may becom public. Cr dit card information should not be included on this form. Provid cr dit card information and auth rizati n n PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.